Aspen Labs Mexico – Carlos Abelleyra Cordero, CEO Spanish LATAM
Aspen Labs wants Latin America to be the third pillar of success for the company, and is doing it in a different way. The CEO for Spanish Latin America discusses…
Ranked as the ninth largest generic company in the world, South African-based Aspen is a supplier of branded and generic pharmaceuticals in more than 150 countries across the world and of consumer and nutritional products in selected territories. The Group currently has 50 business units , 26 manufacturing facilities at 18 sites on 6 continents and approximately 8200 employees. In Latin America Aspen supplies a range of quality affordable products through its affiliate companies in Mexico, Argentina, Brazil and Venezuela as well as across the rest of Latin America in countries such as Chile, Colombia, Ecuador and the Carricam territories. Aspen sees Latin America as one of its key strategic regions with significant growth potential within the Group, and continues to seek opportunities to establish a greater presence in other Latin American countries.
Contact Details
Aspen Labs, S.A. De C.V.
Av. Insurgentes Sur 1685
Col. Guadalupe Inn, Del. Alvaro Obregón
C.P. 01020 México D.F.
Tel: +52 (55) 9126 0860
Website: aspenlabs.com.mx
Aspen Labs wants Latin America to be the third pillar of success for the company, and is doing it in a different way. The CEO for Spanish Latin America discusses…
The Aspen Group identified Latin America as a “large developing market where it can leverage its substantial intellectual property portfolio and manufacturing infrastructure”. What was the original strategy behind getting…
The latest stories from Mexican pharma and healthcare, including Sanfer’s purchase of Colombia-based manufacturer Vitalis; Organon Mexico’s new business; the FDA’s warning to Glicerinas Industriales, and a look at the issues,…
Mexican voters will be heading to the polls next June for what will be the largest election process in the country’s history with concurrent state and federal elections. The election will…
The latest from Mexican pharma, including the distribution agreement between Dow and Azelis, Neuraxpharm’s new LatAm subsidiaries in Mexico and Brazil; Landsteiner Scientific’s restructure, and Merck’s plant expansion in Naucalpan.…
Latin America’s patient organisations are today playing a more important role than ever before in developing solutions to the continent’s most pressing healthcare challenges. Given the healthcare gaps that persist,…
Back in Latin America after several years in the US and Europe, Teva LatAm Head and Mexico GM Rodrigo Fernandez explains how the affiliate has adapted its strategy across the…
Mexico, with the second largest pharmaceutical market in Latin America, has a number of strong local pharma industry players. These companies, no longer focused solely on the domestic market, are…
María del Socorro España Lomelí, the executive director of Mexico’s National Association of Manufacturers of Medicines (ANAFAM), speaks to PharmaBoardroom about ANAFAM’s evolving relationship with the Mexican government and the…
Dagoberto Cortés Cervantes, president of Mexico’s National Association of Medicines Manufacturers (ANAFAM) and director of Grupo Sanfer/Hormona Mexico, outlines the expansion strategy that has led the manufacturing group to extend…
The Mexican Association of Pharmaceutical Research Industries (AMIIF) represents the innovative pharmaceutical industry in Mexico, advocating for innovation and promoting dialogue with local authorities. AMIIF’s Executive Director, Cristobal Thompson, discusses…
Latin America (LatAm) Area Lead for Astellas Sandra Ramirez outlines the Japanese company’s presence in the region, its efforts to partner with local stakeholders to improve patient access, and the…
Mexico’s pharma market, the second largest in Latin America and among the top 15 globally, is set to top USD 13 billion in sales by 2028. Despite the encouraging numbers,…
The director of Mexican pharmaceutical industry association CANIFARMA, Rafael Gual Cosío, speaks out about the current contradictions plaguing Mexico’s pharma sector. Gual Cosío highlights the fact that market growth and…
See our Cookie Privacy Policy Here